Published in Hospital Business Week, November 19th, 2006
The award is a continuation of earlier grants from the National Institutes of Health (NIH) that supported the development of this test. The NIH grant is intended to help the company obtain U.S. Food & Drug Administration (FDA) approval and bring the product to market. Transfusion of bacterially contaminated platelets can result in severe or fatal sepsis, and remains the highest known risk associated with transfusion of blood products.
Screening all platelet...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.